{
    "ticker": "IPHA",
    "name": "Immunome, Inc.",
    "description": "Immunome, Inc. is a biotechnology company focused on harnessing the power of the human immune system to develop innovative therapies for cancer and infectious diseases. Founded in 2015 and headquartered in Exton, Pennsylvania, Immunome's proprietary platform enables the identification and development of novel antibodies that can target a wide range of diseases. The company is particularly known for its work in developing therapeutic candidates that leverage the body's natural immune response to tackle complex diseases. Immunome's lead product candidate is a monoclonal antibody therapeutic derived from the immune response of individuals who have recovered from COVID-19, aiming to provide a potent treatment option. The company is dedicated to advancing its pipeline by employing cutting-edge technologies and collaborating with academic institutions and industry partners. With an emphasis on innovation and efficacy, Immunome strives to contribute significantly to the field of immunotherapy, seeking to improve patient outcomes and quality of life. Their mission is to unlock the potential of the immune system in order to develop safe and effective therapies that can transform the treatment landscape for severe diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Exton, Pennsylvania, USA",
    "founded": "2015",
    "website": "https://www.immunome.com",
    "ceo": "P. A. K. N. D. S. M. M. K. P. S. S. P. S. S.",
    "social_media": {
        "twitter": "https://twitter.com/immunome",
        "linkedin": "https://www.linkedin.com/company/immunome/"
    },
    "investor_relations": "https://investors.immunome.com",
    "key_executives": [
        {
            "name": "P. A. K. N. D. S. M. M. K. P. S. S. P. S. S.",
            "position": "CEO"
        },
        {
            "name": "James A. M. S. H.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "COVID-19 Monoclonal Antibody",
                "Cancer Antibody Therapeutics"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immunome, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore Immunome, Inc., a biotechnology leader developing novel therapies utilizing the immune system to treat cancer and infectious diseases.",
        "keywords": [
            "Immunome",
            "Biotechnology",
            "Immunotherapy",
            "Cancer Treatment",
            "COVID-19 Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Immunome specialize in?",
            "answer": "Immunome specializes in developing innovative therapies using the human immune system to treat cancer and infectious diseases."
        },
        {
            "question": "Who is the CEO of Immunome?",
            "answer": "The CEO of Immunome, Inc. is P. A. K. N. D. S. M. M. K. P. S. S. P. S. S."
        },
        {
            "question": "Where is Immunome headquartered?",
            "answer": "Immunome is headquartered in Exton, Pennsylvania, USA."
        },
        {
            "question": "What are Immunome's main products?",
            "answer": "Immunome's main products include monoclonal antibody therapeutics for COVID-19 and cancer."
        },
        {
            "question": "When was Immunome founded?",
            "answer": "Immunome was founded in 2015."
        }
    ],
    "competitors": [
        "VRTX",
        "BMY",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "AZN",
        "JNJ"
    ]
}